Review
Oncology
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu
Summary: This meta-analysis explored the efficacy and safety of sorafenib in hepatocellular carcinoma patients after radical surgery, revealing that sorafenib can improve overall survival, recurrence-free survival, and reduce recurrence rates without intolerable side effects. More evidence is needed for a definitive conclusion.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Review
Oncology
Liwei Lv, Xuefei Sun, Yuchen Wu, Qu Cui, Yuedan Chen, Yuanbo Liu
Summary: The meta-analysis results of this study showed that ibrutinib has a good treatment effect on patients with central nervous system lymphoma (CNSL) and is well tolerated, providing some benefits to patients. However, more randomized controlled studies are still needed to directly compare the efficacy and adverse events of ibrutinib.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Fanming Kong, Chaoran Wang, Xiaojiang Li, Yingjie Jia
Summary: The combination of Kanglaite (KLT) and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) showed significant efficacy in the treatment of stage III/IV non-small cell lung cancer, improving disease control rate, objective response rate, Karnofsky performance status, and enhancing patient immunity. Additional well-designed studies are needed to further confirm its efficacy and safety.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Nutrition & Dietetics
Arrigo F. G. Cicero, Cormac Kennedy, Tamara Knezevic, Marilisa Bove, Coralie M. G. Georges, Agne Satrauskiene, Peter P. Toth, Federica Fogacci
Summary: Armolipid Plus(R) is a multi-constituent nutraceutical that has been shown to improve lipid profiles, with significant effects on body mass index and various cholesterol levels. Clinical trials also demonstrate that Armolipid Plus(R) is well tolerated and beneficial for improving cardiometabolic health.
Review
Oncology
Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang, Bo Li
Summary: This meta-analysis compares the efficacy and safety of lenvatinib and sorafenib in patients with advanced hepatocellular carcinoma (HCC). The results showed that lenvatinib had significantly better progression-free survival and disease control rate compared to sorafenib, with similar incidences of adverse events. Lenvatinib is a promising alternative to sorafenib as a first-line therapy for advanced HCC.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Nuersimanguli Maimaitiming, Xiaoli Ma, Yu Wei, Leiyu Cao, Yan Gao, Li Zhang
Summary: This study evaluated the role and safety of endostar combined with concurrent chemoradiotherapy in patients with locally advanced cervical carcinoma. The results demonstrated that endostar combined with chemoradiotherapy significantly improved the objective response rate and disease control rate in these patients without increasing adverse reactions.
Review
Medicine, General & Internal
Juan Yang, Xuan Zhou, Qingyu Ma, Jeffrey T. Woods, Arya B. Mohabbat, Alexander Do, Jeffrey S. Brault, Mark A. Jensen, Kyung-Min Shin, Longbin Shen, Canghuan Zhao, Kwok Chee Philip Cheong, Kejie He, Yu Guo, Zhuoming Chen, Shujie Tang, Yong Tang, Celia Ia Choo Tan, Jiaxu Chen, Brent A. Bauer
Summary: This study aimed to systematically evaluate the efficacy and safety of Tuina in the treatment of CNLBP. Fifteen RCTs involving 1390 patients were included. The results showed that Tuina had a significant effect on pain and physical function, but not on quality of life. The evidence quality of the study results was determined to be low level, and more large-scale RCTs are needed to further confirm the findings.
Review
Medicine, General & Internal
Dailong Li, Siqi Liu, Chunlai Cheng, Lu Xu, Pingfan Zhao
Summary: Meta-analysis showed that TACE plus lenvatinib achieved remarkable efficacy in patients with advanced HCC compared with TACE or lenvatinib alone, and the efficacy versus risk need to be carefully balanced in clinical application.
Review
Oncology
Ping Li, Ming Hu, Mei Liu, Xiangyu Ren, Donghong Liu, Jiluo Liu, Jianhua Yin, Xiaojie Tan, Guangwen Cao
Summary: Systemic combinations, especially targeted plus ICI therapy, including Atezo plus Beva, significantly improve clinical outcomes but increase side effects in patients with advanced hepatocellular carcinoma.
FRONTIERS IN ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jaekyung Cheon, Changhoon Yoo, Jung Yong Hong, Han Sang Kim, Dae-Won Lee, Myung Ah Lee, Jin Won Kim, Ilhwan Kim, Sang-Bo Oh, Jun-Eul Hwang, Hong Jae Chon, Ho Yeong Lim
Summary: This study aimed to investigate the safety and efficacy of Atezolizumab plus bevacizumab in real settings for patients with advanced hepatocellular carcinoma. The results showed that Ate/Bev demonstrated real-life efficacy and safety in Korean patients, consistent with the phase III trial results, but showed unfavorable outcomes in patients with elevated NLR.
LIVER INTERNATIONAL
(2022)
Article
Oncology
Xiaoqiang Gao, Rui Zhao, Huaxing Ma, Shi Zuo
Summary: This study assessed the efficacy and tolerability of atezolizumab plus bevacizumab in the treatment of advanced hepatocellular carcinoma (HCC). The results showed that the combination treatment had an overall response rate of 26%, a complete response rate of 2%, and a partial response rate of 23% in long-term therapy. The median overall survival was 14.7 months and the median progression-free survival was 6.66 months. During the treatment, 83% of patients experienced any grade adverse events and 30% experienced grade 3 and above adverse events. In conclusion, atezolizumab plus bevacizumab demonstrated good efficacy and tolerability in the treatment of advanced HCC.
Article
Oncology
Fabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, Jan Best, Thorben Wilhelm Fruendt, Carolin Czauderna, Alica Beutel, Dominik Bettinger, Johannes WeiSS, Tobias Meischl, Fabian Kuetting, Dirk-Thomas Waldschmidt, Pompilia Radu, Michael Schultheiss, Kai-Henrik Peiffer, Thomas J. Ettrich, Arndt Weinmann, Henning Wege, Marino Venerito, Jean-Francois Dufour, Christian M. Lange, Matthias Pinter, Oliver Waidmann
Summary: This study reported real-world data from an international cohort of patients with advanced HCC treated with cabozantinib, showing efficacy and safety in patients with compensated cirrhosis. The median overall survival was 9.7 months in Child-Pugh A patients and 3.4 months in Child-Pugh B patients. Cabozantinib treatment was effective and safe in these patients.
Review
Medicine, General & Internal
Meichen Li, Xin Liu, Xinyi Ye, Lixing Zhuang
Summary: This study systematically evaluated the clinical efficacy of acupuncture in patients with generalized anxiety disorder (GAD). The results showed that acupuncture can effectively relieve anxiety symptoms with fewer side effects. However, further high-quality randomized controlled trials are needed to support these findings.
Article
Immunology
Yujing Xin, Fei Cao, Hongcai Yang, Xinyuan Zhang, Yi Chen, Xiaojing Cao, Xiang Zhou, Xiao Li, Jinxue Zhou
Summary: ATEZ plus bevacizumab combined with HAIC-FOLFOX demonstrated significant therapeutic effect and manageable adverse events in patients with advanced HCC, providing a potential treatment option for advanced HCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jie Shen, Jing Yan, Sihui Zhu, Weiwei Kong, Zhengyun Zou, Juan Liu, Shuangshuang Li, Baorui Liu
Summary: The study investigated the clinical outcomes of HCC patients who received hypofractionated radiotherapy, showing a significant impact on local control rate and overall survival.
FRONTIERS IN ONCOLOGY
(2021)